The Journal of Immunology, Vol 147, Issue 11 3745-3751, Copyright © 1991 by American Association of Immunologists

ARTICLES

Differential stability of antigenic MHC class I-restricted synthetic peptides

C Widmann, JL Maryanski, P Romero and G Corradin
Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland.

Various synthetic peptides recognized as Ag by CTL in the context of MHC class I molecules were tested for stability in vitro and in vivo. Peptide inactivation in vitro was quantitated by titrating the amount of peptide required to sensitize target cells for lysis by specific CTL clones. The degree of inactivation after overnight incubation at 37 degrees C varied widely among a series of antigenic peptides. Some were nearly unaffected, whereas others lost activity by more than 100-fold or even 10,000-fold. However, no correlation was found between susceptibility to serum inactivation and antigenic potency as measured in short term cytolytic assays. No inactivation occurred at 4 degrees C, or at 37 degrees C in the absence of serum, under the conditions used. Serum inactivation most likely involved proteolysis because it could be inhibited by protease inhibitors. Moreover, presumed cleavage products of a radiolabeled susceptible peptide could be visualized by TLC. In vivo, the persistence of the antigenic activity of the injected peptides, either in extracellular fluids or on tumor target cells growing in an ascites form, correlated with the degree of stability found for the peptides in vitro. The differential stability of synthetic peptides may have important consequences for attempts to manipulate the development of an immune response in vivo.

This article has been cited by other articles:

				P. Johansen, T. Storni, L. Rettig, Z. Qiu, A. Der-Sarkissian, K. A. Smith, V. Manolova, K. S. Lang, G. Senti, B. Mullhaupt, et al. Antigen kinetics determines immune reactivity PNAS, April 1, 2008; 105(13): 5189 - 5194. [Abstract] [Full Text] [PDF]

				D. Zehn, C. J. Cohen, Y. Reiter, and P. Walden Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming Int. Immunol., December 1, 2006; 18(12): 1647 - 1654. [Abstract] [Full Text] [PDF]

				M. Amacker, O. Engler, A. R. Kammer, S. Vadrucci, D. Oberholzer, A. Cerny, and R. Zurbriggen Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells Int. Immunol., June 1, 2005; 17(6): 695 - 704. [Abstract] [Full Text] [PDF]

				W. L. Redmond, B. C. Marincek, and L. A. Sherman Distinct Requirements for Deletion versus Anergy during CD8 T Cell Peripheral Tolerance In Vivo J. Immunol., February 15, 2005; 174(4): 2046 - 2053. [Abstract] [Full Text] [PDF]

				L. BenMohamed, A. Thomas, and P. Druilhe Long-Term Multiepitopic Cytotoxic-T-Lymphocyte Responses Induced in Chimpanzees by Combinations of Plasmodium falciparum Liver-Stage Peptides and Lipopeptides Infect. Immun., August 1, 2004; 72(8): 4376 - 4384. [Abstract] [Full Text] [PDF]

				I. P. Hunziker, B. Grabscheid, R. Zurbriggen, R. Gluck, W. J. Pichler, and A. Cerny In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus Int. Immunol., June 1, 2002; 14(6): 615 - 626. [Abstract] [Full Text] [PDF]

				J.-S. Blanchet, D. Valmori, I. Dufau, M. Ayyoub, C. Nguyen, P. Guillaume, B. Monsarrat, J.-C. Cerottini, P. Romero, and J. E. Gairin A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy J. Immunol., November 15, 2001; 167(10): 5852 - 5861. [Abstract] [Full Text] [PDF]

				T. Luft, M. Rizkalla, T. Y. Tai, Q. Chen, R. I. MacFarlan, I. D. Davis, E. Maraskovsky, and J. Cebon Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation J. Immunol., September 1, 2001; 167(5): 2529 - 2537. [Abstract] [Full Text] [PDF]

				D. Valmori, F. Levy, I. Miconnet, P. Zajac, G. C. Spagnoli, D. Rimoldi, D. Lienard, V. Cerundolo, J.-C. Cerottini, and P. Romero Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue J. Immunol., January 15, 2000; 164(2): 1125 - 1131. [Abstract] [Full Text] [PDF]

				M. Ayyoub, H. Mazarguil, B. Monsarrat, B. Van den Eynde, and J. E. Gairin A Structure-based Approach to Designing Non-natural Peptides That Can Activate Anti-melanoma Cytotoxic T Cells J. Biol. Chem., April 9, 1999; 274(15): 10227 - 10234. [Abstract] [Full Text] [PDF]

				D. Accapezzato, R. Nisini, M. Paroli, G. Bruno, F. Bonino, M. Houghton, and V. Barnaba Generation of an MHC Class II-Restricted T Cell Epitope by Extracellular Processing of Hepatitis {delta} Antigen J. Immunol., June 1, 1998; 160(11): 5262 - 5266. [Abstract] [Full Text] [PDF]